PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för GDC-0879. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

7 hits

Bibliografisk träff 2014-08-21

Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.

Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S.

Cancer Cell · research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccr.2014.07.007

Bibliografisk träff 2013-10-15

Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK.

Doma E, Rupp C, Varga A, Kern F, Riegler B, Baccarini M.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-13-0748

Bibliografisk träff 2012-06-01

Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction.

Chou B, Adler RS, Meng M, Percey S, Dean B, Hop CE, Shin YG.

J Pharm Biomed Anal · validation study; journal article · DOI 10.1016/j.jpba.2012.05.029

Bibliografisk träff 2009-09-01

Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.

Choo EF, Driscoll JP, Feng J, Liederer B, Plise E, Randolph N, Shin Y, Wong S, Ran Y.

Xenobiotica · journal article · DOI 10.1080/00498250902991827

Bibliografisk träff 2009-03-10

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res · journal article · DOI 10.1158/0008-5472.can-08-3563

Bibliografisk träff 2009-01-15

Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.

Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.108.148189

Bibliografisk träff 2008-07-05

Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, Brandhuber BJ, Vigers G, Morales T, Woessner R, Randolph N, Lyssikatos J, Olivero A.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.07.002